InMed Pharmaceuticals (INM) Cash from Operations (2019 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Cash from Operations of 1695136.0 for Q1 2026, down 2.15% year-over-year from 1732339.35 in Q1 2025, and up 28.66% quarter-over-quarter from 2376243.0 in Q4 2025.
InMed Pharmaceuticals (INM) Cash from Operations (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 1695136.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 2.15% year-over-year to 1695136.0; the TTM figure through Mar 2026 stood at 7457501.0 (down 6.27% YoY), while the FY2025 annual figure was 7766951.0, down 11.18% from the prior year.
- Cash from Operations for Q1 2026 stood at 1695136.0, up from 2376243.0 in the prior quarter.
- The five-year high for Cash from Operations was 657934.0 in Q2 2023, with the low at 5348786.0 in Q1 2022.
- The 5-year median for Cash from Operations is 1848133.0 (2023), against an average of 2183000.59.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations plunged 101.75% in 2022, then jumped 83.74% in 2023.
- InMed Pharmaceuticals' Cash from Operations stood at 2713096.0 in 2022, then jumped by 31.88% to 1848133.0 in 2023, then plunged by 35.39% to 2502138.0 in 2024, then climbed by 5.03% to 2376243.0 in 2025, then grew by 28.66% to 1695136.0 in 2026.
- Business Quant data shows INM's Cash from Operations at 1695136.0 in Q1 2026, 2376243.0 in Q4 2025, and 1607616.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.56 Mn | 1.32 Mn | - | -1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.70 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Dec 31, 2025 | -2.38 Mn |
| Dec 31, 2025 | -2.38 Mn |
| Sep 30, 2025 | -1.61 Mn |
| Sep 30, 2025 | -1.61 Mn |
| Jun 30, 2025 | -1.78 Mn |
| Jun 30, 2025 | -1.78 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Dec 31, 2024 | -2.50 Mn |
| Dec 31, 2024 | -2.50 Mn |
| Sep 30, 2024 | -1.83 Mn |
| Sep 30, 2024 | -1.83 Mn |
| Jun 30, 2024 | -1.03 Mn |
| Jun 30, 2024 | -1.03 Mn |
| Mar 31, 2024 | -1.93 Mn |
| Mar 31, 2024 | -1.93 Mn |
| Dec 31, 2023 | -1.85 Mn |
| Dec 31, 2023 | -1.85 Mn |